Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy

Anti-Cancer Drugs

Volumn 24, Issue 4, 2013, Pages 422-425

  Gerullis, Holger ^a,b   Eimer, Christoph ^a   Ecke, Thorsten H ^c   Georgas, Evangelos ^a   Arndt, Christian ^a   Otto, Thomas ^a,b  

^a Lukaskrankenhaus GmbH   (Germany)

^b German Centre for Assessment and Evaluation of Innovative Techniques in Medicine DZITM   (Germany)

^c HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

clinical trial; pazopanib; phase I study; second line; urothelial carcinoma; vinflunine

Indexed keywords

PAZOPANIB; PLATINUM DERIVATIVE; VINFLUNINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; LOADING DRUG DOSE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG-INDUCED LIVER INJURY; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; MALE; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PROSPECTIVE STUDIES; PYRIMIDINES; SALVAGE THERAPY; SULFONAMIDES; THROMBOCYTOPENIA; UROLOGIC NEOPLASMS; VINBLASTINE;

EID: 84875055446     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835efe78     Document Type: Article

References (26)

1. Gerullis H, Otto T, Ecke TH. Targeted agents in second-line bladder cancer therapy. Anticancer Drugs 2012; 23:1003-1015
2. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-4461
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257
4. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55:510-513
5. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004; 171:570-574
6. WuW, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003; 22:3361-3370
7. Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 2011; 78:e7-e13
8. Necchi A, Zaffaroni N, Mariani L, Nicolai N, Giannatempo P, Crippa F, et al. Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib in refractory urothelial cancer. Ann Oncol 2012; 23 (Suppl 1):i15-i25
9. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, et al. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. J Clin Oncol 2011; 29 (Suppl):259
10. Clinical trial identifier. http://www.clinicaltrials.gov/ct2/show/ NCT01265940. [Accessed 12 October 2012
11. Edler L. Handbook of statistics in clinical oncology. In: Crowley INJ, Ankerst DP, editors. Handbook of statistics in clinical oncology, chapter 1. Boca Raton: CRC Taylor & Francis 2006. pp. 3-30
12. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14:1149-1161
13. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQC30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365-376
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
15. Campone M, Isambert N, Bourbouloux E, Roche H, Bonneterre J, Milano G, et al. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2012; 69:871-879
16. Sanoff HK, Davies J,Walko C, Buie L, Chiu WK, Ivanova A, et al. Phase I trial of vinflunine and pemetrexed in refractory solid tumors. Invest New Drugs 2011; 29:131-136
17. Sanoff HK, Davies JM, Walko C, Irvin W, Buie L, Keller K, et al. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. Invest New Drugs 2011; 29:978-983
18. Souquet PJ, Krzakowski M, Ramlau R, Sun XS, Lopez-Vivanco G, Puozzo C, et al. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2010; 11:105-113
19. Yardley DA, McCleod M, Schreiber F, Murphy P, Patton J, Thompson DS, et al. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest 2010; 28:925-931
20. Zaman K, Durando X, Baurain JF, Humblet Y, Mazzeo F, Bostnavaron M, et al. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer. Breast Cancer Res Treat 2011; 127:689-696
21. Tournoux-Facon C, Senellart H, Lemarie E, Tourani JM, Favrel S, Pouget JC, et al. Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in hemonaive patients. J Thorac Oncol 2011; 6:1247-1253
22. Pujol JL, Viens P, Rebattu P, Laurie SA, Feld R, Deneulin A, et al. Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol 2006; 1:417-424
23. Chen YM, Liu JM, Chou TY, Perng RP, Tsai CM, Whang-Peng J. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 2007; 109:1821-1828
24. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119:32-37
25. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MG, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077
26. Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638-2646